期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多发性骨髓瘤的CAR-T细胞治疗现状 被引量：6

Advances in CAR-T therapy for patients with multiple myeloma
原文传递
导出
摘要 多发性骨髓瘤（MM）是骨髓恶性浆细胞克隆增殖性疾病，导致骨髓造血受抑和溶骨性疾病。尽管应用传统化疗和造血干细胞移植以及靶向性药物治疗骨髓瘤，MM仍然不能完全治愈。其中一个重要原因就是随着疾病进展而出现的免疫缺陷和免疫耐受。天然免疫系统中，
作者 吴晓菲 王雅丹 胡豫
机构地区 华中科技大学同济医学院附属协和医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2016年第10期921-925,共5页 Chinese Journal of Hematology
基金 国家自然科学基金（81201866） 教育部高等学校博士学科点专项科研基金（20120142120077）
关键词 多发性骨髓瘤 细胞治疗 克隆增殖性疾病 造血干细胞移植 天然免疫系统 骨髓造血 药物治疗 免疫耐受
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献40

  • 1Godfrey J, Benson DM. The role of natural killer cells in immunity against multiple myeloma [J]. Leuk Lymphoma, 2012, 53(9): 1666-1676. doi: 10.3109/10428194.2012.676175.
  • 2Lawrence T, Natoli G. Transcriptional regulation of macrophage polarization: enabling diversity with identity [J]. Nat Rev Immunol, 2011, 11(11): 750-761. doi: 10.1038/nri3088.
  • 3Ratta M, Fagnoni F, Curti A, et al. Dendritic ceils are functional- ly defective in multiple myeloma: the role of interleukin-6 [J]. Blood, 2002, 100( 1 ): 230-237.
  • 4Favaloro J, Brown R, Aklilu E, et al. Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state [J]. Leuk Lymphoma, 2014, 55 (5): 1090- 1098. doi: 10.3109/10428194.2013.825905.
  • 5Stauss HJ, Morris EC, Abken H. Cancer gene therapy with T cell receptors and chimeric antigen receptors [J]. Curr Opin Pharmacol, 2015, 24:113-118. doi: 10.1016/j.coph.2015.08.006.
  • 6Yaecoby S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype [J]. Clin Cancer Res, 2005, 11 (21): 7597606. doi: 10.1158/1078-0432.CCR-05-0523.
  • 7Garfall AL, Maus MV, Hwang WT, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma [J]. N Engl J Med, 2015, 373 (11):1040- 1047. doi: 10.1056/ NEJMoa1504542.
  • 8Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeu- tic antibody target for the treatment of multiple myeloma [J]. Clin Cancer Res, 2008, 14 (9): 2775-2784. doi: 10.1158/1078- 0432.CCR-07-4246.
  • 9Tai YT, Soydan E, Song W, et al. CS1 promotes multiple myeloma cell adhesion, clonogenie growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal ceils [J]. Blood, 2009, 113 (18): 4309-4318. doi: 10.1182/blood- 2008-10-183772.
  • 10Bae J, Song W, Smith R, et al. A novel irnmunogenic CS1- specific peptide inducing antigen- specific cytotoxic T lymphocytes targeting multiple myeloma [J]. Br J Haematol, 2012, 157(6): 687-701. doi: 10.1111/j.1365-2141.2012.09111.x.

二级参考文献16

  • 1Hart AJ, Jagasia MH, Kim AS, et al. Minimal residual disease in myeloma: are we there yet?[J]. Biol Blood Marrow Transplant,2012, 18(12):1790-1799.
  • 2Sadelain M, Brentjens R, Rivière I. The promise and potential pitfalls of chimeric antigen receptors[J]. Curr Opin Immunol,2009, 21(2):215-223.
  • 3Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma[J]. Clin Cancer Res, 2011, 17(6): 1264-1277.
  • 4Rajkumar SV. Treatment of multiple myeloma[J]. Nat Rev Clin Oncol, 2011, 8(8): 479-491.
  • 5Brown CE, Starr R, Aguilar B, et al. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells[J]. Clin Cancer Res, 2012, 18(8): 2199-2209.
  • 6Kershaw MH, Teng MW, Smyth MJ, et al. Supernatural T cells: genetic modification of T cells for cancer therapy[J]. Nat Rev Immunol, 2005, 5(12): 928-940.
  • 7Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J]. N Engl J Med, 2011, 365(8): 725-733.
  • 8Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J]. N Engl J Med, 2013, 368(16): 1509-1518.
  • 9Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia[J]. Sci Transl Med,2013, 5(177): 177ra138.
  • 10Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors[J]. Nat Rev Clin Oncol, 2013,10(5): 267-276.

共引文献4

同被引文献27

引证文献6

二级引证文献9

中华血液学杂志
2016年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部